Real-World Safety of Immune Checkpoint Inhibitors and Clinical Outcomes in Cancer Patients: A Multicenter Study from Saudi Arabia

Background/Objectives: Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment but can induce immune-related adverse events (irAEs), and real-world data from Saudi Arabia remain limited. We aimed to characterize the incidence, timing, and predictors of irAEs and their association with survival. Methods: We conducted a multicenter retrospective cohort study of adults who received at least one ICI dose at two tertiary centers in Riyadh (January 2017–January 2023; follow-up until July 2025). Physician-documented irAEs were extracted from medical records. Predictors were assessed using logistic regression, and progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier methods, with a sensitivity analysis excluding isolated fatigue and a 3-month landmark analysis. Results: Among 608 patients (median age, 62 years; 55.9% male; 77.1% stage IV), 338 (55.6%) developed at least one irAE, most commonly fatigue (23.8%), endocrine events (15.3%), and skin reactions (10.2%). Median time to irAE onset was 84 days, with endocrine events occurring latest (median, 135 days). Hypertension was independently associated with irAE development (adjusted odds ratio, 1.58; 95% confidence interval, 1.04–2.40). Patients with irAEs had longer median PFS (14.26 vs. 6.08 months; p < 0.0001) and OS (26.14 vs. 16.91 months; p = 0.0324). The PFS association persisted after excluding isolated fatigue, whereas the OS association did not; neither was significant in the landmark analysis. Conclusions: In this real-world multicenter cohort, irAEs were common and showed distinct organ-specific onset patterns. Their associations with longer PFS and OS were attenuated after accounting for exposure definition and immortal time bias and should not be interpreted as evidence that irAEs predict treatment benefit.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-17
DOI
https://doi.org/10.3390/cancers18223679
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-World Safety of Immune Checkpoint Inhibitors and Clinical Outcomes in Cancer Patients: A Multicenter Study from Saudi Arabia

Hatoon Bakhribah, Mada Alharbi, Omar A. Almohammed, Fouad H. AlNajjar et al.
4 links
Cancers
Cancer Immunotherapy and Biomarkers
article

Real-World Safety of Immune Checkpoint Inhibitors and Clinical Outcomes in Cancer Patients: A Multicenter Study from Saudi Arabia

Hatoon Bakhribah, Mada Alharbi, Omar A. Almohammed, Fouad H. AlNajjar, Lama Alfehaid, Nada Alsuhebany, Reema Alotaibi, Manar Alsahli, Farah Alsaidy, Ahmed S. Alanazi, Albatoul Alomran, Eman Alzahrani, Norah Alqahtani
article en

Abstract

Background/Objectives: Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment but can induce immune-related adverse events (irAEs), and real-world data from Saudi Arabia remain limited. We aimed to characterize the incidence, timing, and predictors of irAEs and their association with survival. Methods: We conducted a multicenter retrospective cohort study of adults who received at least one ICI dose at two tertiary centers in Riyadh (January 2017–January 2023; follow-up until July 2025). Physician-documented irAEs were extracted from medical records. Predictors were assessed using logistic regression, and progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier methods, with a sensitivity analysis excluding isolated fatigue and a 3-month landmark analysis. Results: Among 608 patients (median age, 62 years; 55.9% male; 77.1% stage IV), 338 (55.6%) developed at least one irAE, most commonly fatigue (23.8%), endocrine events (15.3%), and skin reactions (10.2%). Median time to irAE onset was 84 days, with endocrine events occurring latest (median, 135 days). Hypertension was independently associated with irAE development (adjusted odds ratio, 1.58; 95% confidence interval, 1.04–2.40). Patients with irAEs had longer median PFS (14.26 vs. 6.08 months; p < 0.0001) and OS (26.14 vs. 16.91 months; p = 0.0324). The PFS association persisted after excluding isolated fatigue, whereas the OS association did not; neither was significant in the landmark analysis. Conclusions: In this real-world multicenter cohort, irAEs were common and showed distinct organ-specific onset patterns. Their associations with longer PFS and OS were attenuated after accounting for exposure definition and immortal time bias and should not be interpreted as evidence that irAEs predict treatment benefit.

CancersVol. 18(22)
Princess Nourah bint Abdulrahman University (SA), Riyadh Armed Forces Hospital (SA), King Saud bin Abdulaziz University for Health Sciences (SA), King Faisal Specialist Hospital & Research Centre (SA), King Fahd Medical City (SA), King Saud University (SA), King Abdulaziz Medical City (SA), King Abdullah International Medical Research Center (SA)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon